Finkelstein Thompson LLP Announces Investigation of Astex Pharmaceuticals, Inc. Buyout

WASHINGTON--(BUSINESS WIRE)--The law firm of Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Astex Pharmaceuticals, Inc. (NASDAQ: ASTX) (“Astex” or “the Company”), concerning the Company’s proposed acquisition by Otsuka Holdings Co., Ltd. (TYO: 45780) (“Otsuka”). Under the terms of the merger agreement, Astex shareholders will receive $8.50 in cash for each share of Astex common stock they own. The total transaction is valued at approximately $886 million. At least one analyst has set a target price of $13.00 for Astex shares.